Watson Exits Medicaid Drug Inflation MDL For $79M

Law360, New York (September 16, 2011, 6:50 PM EDT) -- Watson Pharmaceuticals Inc. on Wednesday agreed to pay $79 million to settle part of a Massachusetts multidistrict litigation accusing it and other pharmaceutical companies of overcharging Medicaid by reporting inflated drug values.

The suits in the MDL, which dates back to 2001, accuse a number of drug industry giants of defrauding the U.S. and some state governments by reporting inflated values of a drug's average wholesale price, the basis for calculating Medicaid reimbursements.

Watson, its subsidiary Schein Pharmaceuticals Inc. and relator Ven-A-Care of the Florida Keys...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.